Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IRF4/BATF and interleukin-33 orchestrate development and maintenance of adipose tissue resident regulatory T cells

ABSTRACT: To understand the differentiation of effector Tregs in more detail, we have performed transcriptional profiling of central Tregs and effector Tregs, based on Blimp1 expression. We performed RNA-sequencing of Foxp3+ regulatory T cells, comparing Blimp1/GFP+ and Blimp1/GFP- cells Three biologically independent samples for each condition were sequenced (condition 1: CD4+ CD25high Blimp1/GFP+; condition 2: CD4+ CD25high Blimp1/GFP-); cells were sorted from pooled spleens and lymphnodes of Blimp1/GFP reporter mice

ORGANISM(S): Mus musculus

SUBMITTER: Wei Shi

PROVIDER: E-GEOD-62535 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

IRF4/BATF and interleukin-33 orchestrate development and maintenance of adipose tissue resident regulatory T cells

Project description:To understand the differentiation of effector Tregs in more detail, we have performed transcriptional profiling of central Tregs and effector Tregs, based on Blimp1 expression. We performed RNA-sequencing of Foxp3+ regulatory T cells, comparing Blimp1/GFP+ and Blimp1/GFP- cells

2014-12-11 | GSE62535 | GEO

RNA-seq analysis of transcriptomes of IL35-Treg cells and the Blimp1-Treg cells

Project description:To gain in depth transcriptional information about the two subsets of effector Tregs, we performed RNA-seq analysis to compare the transcriptomes of Thy1.1+Blimp1- (Ebi3-Tregs) and Thy1.1-Blimp1+ (Blimp1-Tregs) Tregs. We found ~173 unique genes with differential expression between the two effector subsets.

2019-08-31 | GSE103456 | GEO

miRNA expression in Tregs from HSCT patients

2011-12-01 | GSE26769 | GEO

The potential binding partners of PARK7/DJ-1 in primary human CD4 regulatory (Tregs) and effector T cells (Teffs)

Project description:PARK7/DJ-1 affinity purification mass spec (AP-MS) in primary human CD4 regulatory (Tregs) and effector T cells (Teffs)

2019-12-04 | MSV000084659 | MassIVE

TGFb dependent Treg conversion and the inhibition of conversion by IL6

Project description:Analysis of CD4+ cells activated with anti-CD3 and cultured in the presence of IL2. The effects of TGFb and IL6 on Treg conversion were analyzed to discover methods of inhibiting Treg conversion and/or Treg functional inhibition. CD4+ T-cells were enriched from lymph nodes of Foxp3-GFP mice and cultured under the under the following conditions: 1) anti-CD3+IL2; 2) anti-CD3+IL2+TGFβ; 3) anti-CD3+IL2+TGFβ+IL6; and 4) anti-CD3+IL2+IL6. On day 4 cells were collected, stained with anti-CD4-PE, and sorted into CD4+FOXP3- and CD4+FOXP3+ populations (>95% purity). For each treatment condition T-effector cells and Tregs were labeled independently (either cy3 or cy5) and hybridized together for a two-color array experiment. Each treatment condition had dye swapped replicates, and a minimum of 3 replicate in total.

2010-03-25 | GSE21027 | GEO

miRNA expression in Tregs from HSCT patients

Project description:The aim of the study was to identify the miRNA expression profile of CD4+CD25high Tregs in SCT patients with and without GvHD early and late after transplantation compared to healthy donors. pool of n = 3 patients without GvHD early (< d100) and late (> d100) after SCT, n=3 patients with GvHD early (< d100) and late (> d100) after SCT and n = 3 sex- and age matched healthy donors for every timepoint

2011-12-01 | E-GEOD-26769 | biostudies-arrayexpress

Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients

Project description:Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to suppress antitumor immune response, may influence long-term clinical outcome (i.e. radiological response, progression-free survival or overall survival) in metastatic colorectal cancer patients treated with a standard first-line chemotherapy including fluorouracil, irinotecan and bevacizumab

| 2120409 | ecrin-mdr-crc

Population gene expression of anti-viral CD4 T cells in Bcl6 and Blimp1 deficient conditions

Project description:Population gene expression of effector CD4+ T cells WT, Bcl6-deficient , Blimp1-deficient or Bcl6 Blimp1-deficient was determined by RNAseq after LCMV Armstrong infection

2021-11-05 | GSE149597 | GEO

TGFb dependent Treg conversion and the inhibition of conversion by IL6

Project description:Analysis of CD4+ cells activated with anti-CD3 and cultured in the presence of IL2. The effects of TGFb and IL6 on Treg conversion were analyzed to discover methods of inhibiting Treg conversion and/or Treg functional inhibition. CD4+ T-cells were enriched from lymph nodes of Foxp3-GFP mice and cultured under the under the following conditions: 1) anti-CD3+IL2; 2) anti-CD3+IL2+TGFÎ²; 3) anti-CD3+IL2+TGFÎ²+IL6; and 4) anti-CD3+IL2+IL6. On day 4 cells were collected, stained with anti-CD4-PE, and sorted into CD4+FOXP3- and CD4+FOXP3+ populations (>95% purity). For each treatment condition T-effector cells and Tregs were labeled independently (either cy3 or cy5) and hybridized together for a two-color array experiment. Each treatment condition had dye swapped replicates, and a minimum of 3 replicate in total. Two color experiment. Four conditions : 1) anti-CD3+IL2, 3 samples 2) anti-CD3+IL2+TGFÎ², 3 samples 3) anti-CD3+IL2+TGFÎ²+IL6, 4 samples 4) anti-CD3+IL2+IL6, 3 samples

2010-04-07 | E-GEOD-21027 | biostudies-arrayexpress

Single-cell gene expression of anti-viral CD4 T cells in Bcl6 and Blimp1 deficient conditions

Project description:Single-cell gene expression of effector CD4+ T cells WT, Bcl6-deficient , Blimp1-deficient or Bcl6 Blimp1-deficient was determined by scRNAseq after LCMV Armstrong infection

2021-11-05 | GSE149912 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data